We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
Read MoreHide Full Article
Key Takeaways
Shares of MIST plunged 66.2% since the CRL issuance, reflecting the delay in the launch of Cardamyst.
The company's shares have lost 67.8% so far this year against the industry's 2.2% growth.
Despite this regulatory roadblock, analysts remain cautiously optimistic about the drug's prospects.
Milestone Pharmaceuticals (MIST - Free Report) recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil) nasal spray. This drug is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition characterized by sudden, rapid heartbeats.
While the CRL raises no concerns about the clinical safety or efficacy of etripamil, it points to two key Chemistry, Manufacturing, and Controls (“CMC”) issues that must be addressed before approval can be granted.
Shares of MIST plunged 66.2% since the CRL issuance, reflecting the delay in the launch of Cardamyst. The company’s shares have lost 67.8% so far this year against the industry’s 2.2% growth. The S&P 500 Index has declined 5.6% in the same period.
Image Source: Zacks Investment Research
Key Regulatory Issues Identified
The first issue highlighted by the FDA pertains to nitrosamine impurities. The agency has requested additional data based on newly issued draft guidance that was published after MIST’s NDA submission. Nitrosamines, which can pose carcinogenic risks when present above acceptable levels over prolonged exposure, have become an increasing area of focus for regulatory scrutiny in pharmaceutical products.
The second issue is related to an inspection of a facility involved in the drug’s release testing. This facility underwent a change in ownership during the NDA review, necessitating a compliance evaluation to ensure adherence to Current Good Manufacturing Practices (cGMP).
Analyst and Market Reactions
Despite this regulatory roadblock, analysts remain cautiously optimistic about the drug’s prospects. They are of the view that Milestone Pharmaceuticals can successfully resolve the identified concerns, suggesting a potential commercial launch in 2026. However, this timeline represents a delay from the company’s original expectations of a mid-2025 launch. Given the complexity of regulatory processes, even this revised estimate could be subject to further adjustments depending on the pace of resolution and regulatory feedback.
MIST’s Response and Next Steps
Milestone Pharmaceuticals has responded swiftly to the CRL, stating its intent to request a Type A meeting with the FDA to clarify the path forward. The company has emphasized its commitment to working collaboratively with the agency to address the outstanding issues and advance the approval process. This is not the first regulatory challenge faced by the company. In December 2023, MIST received a refusal-to-file letter from the FDA, requiring modifications to its initial NDA submission before it could be considered for full review.
Financially, Milestone Pharmaceuticals appears to be well-positioned to navigate this regulatory challenge. As of Dec. 31, 2024, the company reported $69.7 million in cash, cash equivalents, and short-term investments. While this liquidity provides a runway to manage ongoing development efforts, additional capital may be required if delays persist.
For investors, the CRL represents a temporary obstacle rather than a fundamental rejection of CARDAMYST’s therapeutic potential. The absence of clinical concerns is a positive indicator for eventual approval, provided MIST can effectively address the CMC-related feedback. However, regulatory unpredictability remains a key risk factor and investors should closely monitor upcoming developments, particularly the outcome of the company’s planned discussions with the FDA.
Milestone Pharmaceuticals currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Cencora, Inc. (COR - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 20% for 2025. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.41%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have gained 1.4% against the industry’s 4.5% decline so far this year.
Cencora, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.1%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 4.9%.
Cencora’s shares have gained 23.5% compared to the industry’s 4.2% improvement year to date.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.
Boston Scientific’s shares have rallied 13.4% compared with the industry’s 7.6% growth so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
Key Takeaways
Milestone Pharmaceuticals (MIST - Free Report) recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil) nasal spray. This drug is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition characterized by sudden, rapid heartbeats.
While the CRL raises no concerns about the clinical safety or efficacy of etripamil, it points to two key Chemistry, Manufacturing, and Controls (“CMC”) issues that must be addressed before approval can be granted.
Shares of MIST plunged 66.2% since the CRL issuance, reflecting the delay in the launch of Cardamyst. The company’s shares have lost 67.8% so far this year against the industry’s 2.2% growth. The S&P 500 Index has declined 5.6% in the same period.
Image Source: Zacks Investment Research
Key Regulatory Issues Identified
The first issue highlighted by the FDA pertains to nitrosamine impurities. The agency has requested additional data based on newly issued draft guidance that was published after MIST’s NDA submission. Nitrosamines, which can pose carcinogenic risks when present above acceptable levels over prolonged exposure, have become an increasing area of focus for regulatory scrutiny in pharmaceutical products.
The second issue is related to an inspection of a facility involved in the drug’s release testing. This facility underwent a change in ownership during the NDA review, necessitating a compliance evaluation to ensure adherence to Current Good Manufacturing Practices (cGMP).
Analyst and Market Reactions
Despite this regulatory roadblock, analysts remain cautiously optimistic about the drug’s prospects. They are of the view that Milestone Pharmaceuticals can successfully resolve the identified concerns, suggesting a potential commercial launch in 2026. However, this timeline represents a delay from the company’s original expectations of a mid-2025 launch. Given the complexity of regulatory processes, even this revised estimate could be subject to further adjustments depending on the pace of resolution and regulatory feedback.
MIST’s Response and Next Steps
Milestone Pharmaceuticals has responded swiftly to the CRL, stating its intent to request a Type A meeting with the FDA to clarify the path forward. The company has emphasized its commitment to working collaboratively with the agency to address the outstanding issues and advance the approval process. This is not the first regulatory challenge faced by the company. In December 2023, MIST received a refusal-to-file letter from the FDA, requiring modifications to its initial NDA submission before it could be considered for full review.
Financially, Milestone Pharmaceuticals appears to be well-positioned to navigate this regulatory challenge. As of Dec. 31, 2024, the company reported $69.7 million in cash, cash equivalents, and short-term investments. While this liquidity provides a runway to manage ongoing development efforts, additional capital may be required if delays persist.
For investors, the CRL represents a temporary obstacle rather than a fundamental rejection of CARDAMYST’s therapeutic potential. The absence of clinical concerns is a positive indicator for eventual approval, provided MIST can effectively address the CMC-related feedback. However, regulatory unpredictability remains a key risk factor and investors should closely monitor upcoming developments, particularly the outcome of the company’s planned discussions with the FDA.
Milestone Pharmaceuticals Inc. Price
Milestone Pharmaceuticals Inc. price | Milestone Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Milestone Pharmaceuticals currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Cencora, Inc. (COR - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 20% for 2025. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.41%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have gained 1.4% against the industry’s 4.5% decline so far this year.
Cencora, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.1%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 4.9%.
Cencora’s shares have gained 23.5% compared to the industry’s 4.2% improvement year to date.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.
Boston Scientific’s shares have rallied 13.4% compared with the industry’s 7.6% growth so far this year.